Abstract 100P
Background
Colorectal cancer ranks as the third most prevalent cancer globally and stands as the second primary contributor to cancer-related mortality. Utilization of a phenomic data approach allows researchers to reveal the mechanisms and molecular pathogenesis of colorectal cancer. We aimed to investigate the correlation between the phenomic features and colorectal cancer in a large cohort study.
Methods
We included 502369 subjects aged 37-73 years in the UK Biobank recruited since 2006. In total, 59 parameters exploring socio-demographic factors, blood chemistry, anthropometric measurements and lifestyle factors of participants collected at baseline assessment were analysed. Univariate and multivariate logistic regression were conducted to examine the associations of these parameters with colorectal cancer risk, based on the odds ratio (OR) and 95% confidence intervals (CI).
Results
The analysis included a total of 438625 participants, of which 5436 (1.2%) were incident colorectal cancer cases and 433189 were healthy controls. A marker, cystatin C was associated with colorectal cancer (adjusted OR 2.11; 95% CI 1.92-2.32). Compared to Asians, Whites ethnicity had higher risk of developing colorectal cancers (adjusted OR 2.54; 95% CI 1.93-3.34). In addition to colorectal cancer, Cystatin C and ethnicity are consistently associated with total gastrointestinal cancers. Cystatin C and ethnicity appear to be important features in GI cancers, suggesting some overlap in the molecular pathogenesis of GI cancers.
Conclusions
Cystatin C and ethnicity emerged as a consistent biomarker associated with different types of gastrointestinal cancers, including colorectal cancer. In order to provide more in-depth understanding of how these factors were associated with gastrointestinal cancers and shed light on the molecular pathogenesis of gastrointestinal cancers, future research will employ a multi-modal approach exploring the genomics and proteomics of the UK Biobank cohort.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
62P - Combination of chemotherapy with endocrinal therapy as upfront treatment of metastatic breast cancer in hormone receptor- positive, HER2 -negative disease: A phase II randomised clinical trial
Presenter: Mariam Saleh
Session: Poster Display
Resources:
Abstract
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract